Figure 3. Progression-Free Survival (PFS) and Overall Survival (OS) by Molecular Subtype and Integrated Risk Stratification in the Validation Cohort.

The x-axes represent time in months after randomization in the New EPOC randomized clinical trial. Of 147 total patients, PFS events occurred in 113, 16, 63, and 34 patients in the overall cohort and immune, canonical, and stromal subtypes, respectively, and OS events occurred in 75, 9, 43, and 23 patients, respectively. By integrated clinical-molecular risk group (n = 144), PFS events occurred in 9, 15, and 86 patients in the low-, intermediate-, and high-risk groups, respectively, and OS events occurred in 3, 10, and 61 patients, respectively.